PROGENICS PHARMACEUTICALS IN's ticker is PGNX and the CUSIP is 743187106. A total of 120 filers reported holding PROGENICS PHARMACEUTICALS IN in Q1 2016. The put-call ratio across all filers is 2.18 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2020 | $275,000 | -21.4% | 72,429 | +5.3% | 0.00% | 0.0% |
| Q4 2019 | $350,000 | +2.0% | 68,813 | +1.3% | 0.00% | 0.0% |
| Q3 2019 | $343,000 | -16.1% | 67,902 | +2.4% | 0.00% | 0.0% |
| Q2 2019 | $409,000 | +36.8% | 66,326 | +2.9% | 0.00% | 0.0% |
| Q1 2019 | $299,000 | +20.1% | 64,488 | +8.6% | 0.00% | 0.0% |
| Q4 2018 | $249,000 | -31.6% | 59,369 | +2.2% | 0.00% | 0.0% |
| Q3 2018 | $364,000 | -10.6% | 58,064 | +14.8% | 0.00% | 0.0% |
| Q2 2018 | $407,000 | +18.7% | 50,571 | +10.0% | 0.00% | 0.0% |
| Q1 2018 | $343,000 | +33.5% | 45,972 | +6.3% | 0.00% | 0.0% |
| Q4 2017 | $257,000 | -17.6% | 43,263 | +2.0% | 0.00% | 0.0% |
| Q3 2017 | $312,000 | +8.3% | 42,410 | +0.1% | 0.00% | 0.0% |
| Q2 2017 | $288,000 | -23.0% | 42,380 | +6.8% | 0.00% | -50.0% |
| Q1 2017 | $374,000 | -16.9% | 39,670 | -61.6% | 0.00% | 0.0% |
| Q1 2016 | $450,000 | -28.9% | 103,280 | 0.0% | 0.00% | -33.3% |
| Q4 2015 | $633,000 | – | 103,280 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Broadfin Capital, LLC | 8,951,169 | $54,871,000 | 3.38% |
| Virtus ETF Advisers LLC | 103,807 | $636,000 | 1.75% |
| BKS ADVISORS, LLC | 291,150 | $1,785,000 | 0.92% |
| Piermont Capital Management Inc. | 363,549 | $2,229,000 | 0.71% |
| TUDOR INVESTMENT CORP ET AL | 2,370,760 | $14,532,000 | 0.41% |
| SEARLE & CO. | 60,000 | $349,000 | 0.34% |
| TURNER INVESTMENTS LLC | 252,785 | $1,550,000 | 0.32% |
| RICE HALL JAMES & ASSOCIATES, LLC | 891,672 | $5,466,000 | 0.31% |
| Phocas Financial Corp. | 635,333 | $3,895,000 | 0.30% |
| TFS CAPITAL LLC | 398,283 | $2,441,000 | 0.26% |